{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Peritoneal&page=31", "query": { "condition": "Cancer Peritoneal", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 911, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Peritoneal&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Peritoneal&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T22:38:56.727Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06885697", "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma", "Neoplasms", "Stomach Neoplasms", "Pancreatic Neoplasms", "Ovarian Neoplasms", "Lung Neoplasms", "Thymus Neoplasms", "Colonic Neoplasms" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "TNhYP218 CAR T Cells", "type": "BIOLOGICAL" }, { "name": "mesothelin expression testing", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 120, "start_date": "2025-07-08", "completion_date": "2044-06-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06885697" }, { "nct_id": "NCT01821859", "title": "Abraxane/Bevacizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "Abraxane", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5, "start_date": "2010-01", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2013-07-26", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01821859" }, { "nct_id": "NCT06714617", "title": "Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer Stage III", "HER2-positive Metastatic Breast Cancer", "Unresectable Breast Carcinoma", "Her2-Positive", "HER2 Gene Mutation", "Gastroesophageal-junction Cancer", "Non Small Cell Lung Cancer", "Endometrial Neoplasms", "Peritoneal Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Urothelial Carcinoma Bladder", "Solid Tumor, Adult", "Gastric Cancer" ], "interventions": [ { "name": "BL-M17D1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SystImmune Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2025-04-10", "completion_date": "2026-01-30", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 9, "location_summary": "Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06714617" }, { "nct_id": "NCT00016289", "title": "Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Peritoneal Cavity Cancer", "Recurrent Ovarian Epithelial Cancer" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2001-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016289" }, { "nct_id": "NCT02228889", "title": "RCT of Two Noncrosslinked Porcine Acellular Dermal Matrices in Ab Wall Reconstruction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hernia, Ventral", "Intestinal Fistula", "Fibromatosis, Abdominal" ], "interventions": [ { "name": "Abdominal wall reconstruction with Strattice", "type": "PROCEDURE" }, { "name": "Assess pain intensity at last office visit preoperatively", "type": "OTHER" }, { "name": "Assess pain interference at last office visit preoperatively", "type": "OTHER" }, { "name": "Assess physical functioning at last office visit preoperatively", "type": "OTHER" }, { "name": "Assess patient quality of life at last office visit preoperatively", "type": "OTHER" }, { "name": "Assess patient pain intensity postoperatively", "type": "OTHER" }, { "name": "Assess pain interference postoperatively", "type": "OTHER" }, { "name": "Assess physical functioning postoperatively", "type": "OTHER" }, { "name": "Assess quality of life postoperatively", "type": "OTHER" }, { "name": "Assess hernia recurrence at 30 days postoperatively", "type": "OTHER" }, { "name": "Assess bulge at 30 days postoperatively", "type": "OTHER" }, { "name": "Assess Surgical Site Occurrences at 30 days postoperatively", "type": "OTHER" }, { "name": "Assess hernia recurrence at 1 year postoperatively", "type": "OTHER" }, { "name": "Assess bulge at 1 year postoperatively", "type": "OTHER" }, { "name": "Assess Surgical Site Occurrences at 1 year postoperatively", "type": "OTHER" }, { "name": "Assess overall complications at 30 days postoperatively", "type": "OTHER" }, { "name": "Assess overall complications at 1 year postoperatively", "type": "OTHER" }, { "name": "Abdominal wall reconstruction with XenMatrix", "type": "PROCEDURE" }, { "name": "Strattice", "type": "DEVICE" }, { "name": "XenMatrix", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DEVICE" ], "sponsor": "Jeffrey Janis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 46, "start_date": "2015-01", "completion_date": "2025-03-27", "has_results": true, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02228889" }, { "nct_id": "NCT05053750", "title": "TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Epithelial Ovarian", "Fallopian Tube", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Paclitaxel/Bev (control)", "type": "DRUG" }, { "name": "Paclitaxel/Bev + ZA (experimental)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2021-12-14", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05053750" }, { "nct_id": "NCT02283658", "title": "Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Endometrioid Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Primary Peritoneal Carcinoma", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2014-11-14", "completion_date": "2018-06-21", "has_results": true, "last_update_posted_date": "2020-10-23", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02283658" }, { "nct_id": "NCT00003704", "title": "Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "1999-04", "completion_date": "2003-07", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003704" }, { "nct_id": "NCT02346747", "title": "A Trial of Vigil for Participants With Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasms" ], "interventions": [ { "name": "Vigil", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "2015-02", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 26, "location_summary": "Mobile, Alabama • Irvine, California • San Francisco, California + 22 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02346747" }, { "nct_id": "NCT01283035", "title": "A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Sarcoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 6, "start_date": "2011-04", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-06-24", "last_synced_at": "2026-11-01T22:38:56.727Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Newton, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01283035" } ] }